By Colin Kellaher

 

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Tuesday said the European Commission approved the use of Imbruvica in two additional indications.

Janssen said Imbruvica is now approved in combination with obinutuzumab in adults with previously untreated chronic lymphocytic leukemia, and in combination with rituximab for adults with Waldenstrom's macroglobulinemia, a rare and incurable type of non-Hodgkin's lymphoma.

The European Medicines Agency's Committee for Medicinal Products for Human Use in June recommended EC approval of the expanded use of Imbruvica.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

August 13, 2019 07:38 ET (11:38 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Johnson and Johnson Charts.